Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis

- Corixa Corporation

Compositions and methods for preventing, treating and detecting leishmaniasis and stimulating immune responses in patients are disclosed. The compounds provided include polypeptides that contain at least an immunogenic portion of one or more Leishmania antigens, or a variant thereof. Vaccines and pharmaceutical compositions comprising such polypeptides are also provided and may be used, for example, for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmania infection.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. An isolated polypeptide comprising an immunogenic portion of a Leishmania antigen having the amino acid sequence recited in SEQ ID NO: 4, or a variant of said antigen that differs only in conservative substitutions, modifications or combinations thereof.

2. The polypeptide of claim 1, comprising amino acids 1-175 of SEQ ID NO:4.

Referenced Cited
Other references
  • Bixler et al, .COPYRGT.1987, In: Synthetic Vaccines Ed. Arnon. pp. 39-71. Houghten 1986 Vaccines 86, pp. 21-25. Bowie et al, 1990. Science, 247:1306-1310. Skeiky et al., "A Recombinant Leishmania Antigen that Stimulates Human Peripheral Blood Mononuclear Cells to Express a Th1-Type Cytokine Profile and to Produce Interleukin 12," Journal of Experimental Medicine 181(4): 1527-1537, 1995. Skeiky et al., "Proliferative and Cytokine Responses of Human PBMC to Cloned Leishmania Braziliensis Heat shock and Ribosomal Antigens,", Journal of Immunology 150(8 pt. 2): 93A, Abstract #517, 1993. Shapira and Pedraza, "Sequence analysis and transcriptional activation of heat shock protein 83 of Leishmania mexicana amazonensis," Molecular and Biochemical Parasitology 42(2): 247-255, 1990. De Andrade et al., "Recombinant Leishmania Hs90 and Hsp70 Are Recognized by Sera from Visceral Leishmaniasis Patients but Not Chagas' Disease Patients," Journal of Clinical Microbiology 30(2): 330-5, 1992. Mougneau et al., "Expression Cloning of a Protective Leishmania Antigen, " Science 268: 563-566, 1995. Campos-Neto et al, "Cloning and Expression of a Leishmania donovani Gene Instructed by a Peptide Isolated from Major Histocompatibility Complex Class II Molecules of Infected Macrophages," Journal of Experimental Medicine 182(5): 1423-1433, 1995. EMBL Database Entry LDP23CSPR, Accession No. X86551, "L. donovani mRNA for 23 kDa cell surface protein," Apr. 26, 1995. Pir2 Database, Accession No. S54162, "Leishmania donovani," Jul. 8, 1995. Frommel et al., "Vaccine-Induced Immunity against Cutaneous Leishmaniasis in BALB/c Mice,"Infection and Immunity 56(4): 843-848, 1988. Dillon et al., "Characterization of a Leishmania tropica antigen that detects immune reponses in Desert Storm viscerotropic leishmaniasis patients," Proc. Natl. Acad. Sci. USA 92: 7981-7985, 1995.
Patent History
Patent number: 5834592
Type: Grant
Filed: Sep 22, 1995
Date of Patent: Nov 10, 1998
Assignee: Corixa Corporation (Seattle, WA)
Inventors: Steven G. Reed (King, WA), Antonio Campos-Neto (King, WA), John R. Webb (King, WA), Davin C. Dillon (King, WA), Yasir A. W. Skeiky (King, WA)
Primary Examiner: Nita Minnifield
Law Firm: Seed and Berry LLP
Application Number: 8/533,669
Classifications
Current U.S. Class: Proteins, I.e., More Than 100 Amino Acid Residues (530/350); Separation, Purification Or Synthesis (530/364); Antigenic Peptides Or Proteins (530/806); 424/2691; 424/1841; Parasitic Peptide Or Parasitic Protein (see Note 6) (930/210)
International Classification: C07K 100; C07K 1400; C07K 1700; A61K 39002;